-
J Clin Oncol: Rituximab + Lenalidomide + Ibrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Time of Update: 2022-08-19
This is an investigator-initiated, single-arm, Phase 2 clinical trial that enrolled 60 patients with newly diagnosed non-germinal center B-cell-like DLBCL to receive rituximab (375 mg/m2, day 1) , lenalidomide (25 mg/day, days 1-10) and ibrutinib (560 mg/day) (RLI) were treated sequentially, with 21 days as a course of treatment .
-
Cardiovasc Diabetol: Reduced miR-21/ROS/HNE levels are associated with hypoglycemia after habitual intervention
Time of Update: 2022-04-21
The relationship between lower miR-21 levels (1 year) and glycemic parameters (baseline) was assessed with logistic regression models to predict the effectiveness of diet and lower blood glucose levels in relatives .
-
Lancet Respir Med: The impact of colchicine on the prognosis of COVID-19 patients
Time of Update: 2021-12-03
The median discharge survival time (10 days; IQR, 5 ~ >28]) of the two groups of patients was the same, and there was no difference in the proportion of patients discharged from the hospital within 28 days (3901 cases in the colchicine group [70%], 4032 cases in the conventional treatment group [70% ]; RR=0.
-
The influence of non-Saccharomyces cerevisiae on wine style
Time of Update: 2021-11-02
Yeast converts the sugars in grape juice into ethanol and CO2, and generates a series of alcohols, esters, aldehydes, organic acids and other products through metabolism during the fermentation process, which affect the quality of wine .
-
Physical and chemical properties and uses of abamectin drugs
Time of Update: 2021-10-22
Among them, the most successful example is the selective reduction of the double bond at the C-22 and C-23 positions of the B1 component to form ivermectin (IVM); doramectin (DOR) is used in AVM C-25 is connected with a six-membered ring to synthesize; eprinomectin (EPR) introduces an acetylamino group through the 4" end of AVM, which can be accomplished by glycosylation or direct synthesis .
-
BJD: Observation of the continuous efficacy of Skuchiyuumab in the treatment of moderate to severe palmoplantar psoriasis
Time of Update: 2021-09-19
5 years) safety and effectiveness of subcutaneous injection of Suckinumab 150 and 300 mg in 205 patients with moderate to severe palmoplantar psoriasis (PpPsO) .
5 years) safety and effectiveness of subcutaneous injection of Suckinumab 150 and 300 mg in 205 patients with moderate to severe palmoplantar psoriasis (PpPsO) .
-
2021 EBMT | Allo-HCT followed by bortezomib in the treatment of MM can significantly reduce the incidence of moderate/severe cGVHD
Time of Update: 2021-03-27
hypothesized that the use of bortezomib (BTZ) maintenance therapy after allo-HCT could reduce the recurrence rate and the incidence of cGVHD in high-risk, young MM patients, and conducted clinical studies to try to determine the effect of bone marrow measurable residual disease (MRD) The impact of future disease progression.
-
Announcement of the Beijing Food and Drug Administration on food safety supervision and sampling information for 2018 (No. 65
Time of Update: 2021-01-07
In accordance with the requirements of the Food Safety Law of the People's Republic of China and other laws and regulations, as well as the city's 2018 food safety supervision and sampling plan and th
-
Immunohistochemistry on fixed, paraffin-embedded sections
Time of Update: 2020-10-28
4- blot the slides without washing and apply the primary antibody (100µl), in a moist chamber, at RT for 1-18 hr.
[8 and 9 are optional] 8- add the AP conjugated tertiary antibody (50 to 100 µl) and incubate for 15 min.
-
Baron-cycle-ether ether
Time of Update: 2020-06-12
Extraction source: This product is grass plants bathina Morinda of ficinalis How's root extracted cyclene ether teriosides, the total cyclene ether terioside content of 80% main ingredient: Cryst
-
Polyphenol supplements can improve the overall ability of aerobic exercise
Time of Update: 2017-05-23
Not long ago, a study published in the Journal of nutrition found that the use of polyphenol rich supplements before exercise increased the overall ability of aerobic exercise by 5%, and the maximum p
-
FDA approved xgeva for hypercalcemia of malignant tumor
Time of Update: 2014-12-12
Source: on December 8, 2014, DXY Amgen announced that the US FDA increased the indication range of xgeva (dinosemide), which can be used in the treatment of bisphosphonate resistant malignant tumor hy
